BGIM
ANIK icon

Brandywine Global Investment Management’s Anika Therapeutics ANIK Stock Holding History

Brandywine Global Investment Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-5,800
Closed -$239K – 984
2015
Q1 		$239K Hold
5,800
– – ﹤0.01% 705
2014
Q4 		$237K Buy
+5,800
New +$227K ﹤0.01% 720

Other funds holding ANIK

TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
LCP
Lombardia Capital Partners Pasadena, California $110M AUM 13.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

Brandywine Global Investment Management's ANIK Position: Q2 2015 in Review

Brandywine Global Investment Management sold out of Anika Therapeutics (ANIK) in Q2 2015, closing a stake of 5,800 shares — an estimated $239K sold.

Brandywine Global Investment Management first reported a position in ANIK in Q4 2014 and held it in 2 quarters. The position peaked at $239K in Q1 2015. 136 funds tracked by Wall St. Rank hold ANIK as of Q2 2015.

  • Brandywine Global Investment Management reported no remaining Anika Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Brandywine Global Investment Management sold 5,800 Anika Therapeutics shares in Q2 2015, an estimated $239K.
  • Brandywine Global Investment Management first reported a position in Anika Therapeutics in Q4 2014 and held it in 2 quarters.
  • Brandywine Global Investment Management's Anika Therapeutics position peaked at $239K in Q1 2015.
  • 136 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2015.

Based on Brandywine Global Investment Management's 13F filing for Q2 2015, filed 14 Aug 2015.